Bristol Myers Squibb news from FiercePharma
News
ImClone rejects BMS's higher bid
The only Bristol-Myers Squibb representative on the ImClone's board of directors, John Celentano, resigned in the wake of what many are now calling a hostile takeover attempt by Bristol-Myers. But... Read more...
Rumor mill: BMS positioning itself for sale
Speculation that Bristol-Myers Squibb might be a takeover target -- that's old news. Informed speculation based on certain strategic moves BMS has made recently -- worth passing on. Tim Anderson, the... Read more...
Setback for Lilly, gain for Plavix?
SPOTLIGHT: Setback for Lilly, gain for Plavix?When FDA delayed its decision on Eli Lilly's clot-buster prasugrel, a.k.a. Effient, it sliced at least three months off the time Lilly might have to win... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
